EuroQuity Blog

The next Belgian e-pitch session will be held online on Thursday 19 December, from 5 to 6 PM CEST !



The next Belgian e-pitch session will be held online on Thursday 19 december, from 5 to 6 PM CEST.  Register here  
Companies will each have 8 minutes to pitch, and investors will ask questions via a chat window throughout the pitch. The company profiles and their pitch deck will be uploaded on the EuroQuity platform, so don’t miss to sign up.
 
The selection is the following :
_______________

The selection is as follows:

MedTech - Medical prediction solution for young asthmatics
A predictive home monitoring solution that allows early diagnosis and revolutionizes the management of chronic respiratory diseases in children aged 0 to 5 years. The dedicated monitoring tool as well as the connected and predictive analysis platform provides parents and physicians with unique data to improve treatment efficiency and anticipate complications. Supported by opinion leaders in the sector. ISO13485 certification in progress.
The partners: Johnson&Johnson (JLABS) and CHU Charleroi | MVP completed - pre-commercialization | Amount sought: €2.5m

MedTech - What if we could add 7 to 12 quality-adjusted life years to people with Parkinson's disease at a 20 to 40% lower cost?
Our platform captures data and detects events in the daily activities of patients with neurodegenerative diseases using state-of-the-art technologies in motion capture, quality of life surveys, portable systems and voice detection. Using AI, data are analyzed and transformed into objective parameters of disease progression to provide an overview of care pathway adherence, treatment outcomes, drug efficacy and personalized care that can be shared with all stakeholders.
The partners: Multitel, CHU Liège, KULeuven, Texas A&M, Northwestern Medicine, Patient Associations | Amount sought: €3.0m

Medtech - device for the treatment of mitral valve regurgitation
Company dedicated to the development and commercialization of a new device for the treatment of mitral valve regurgitation by mitral valve repair (minimal invasive procedures). The device will allow physicians to treat mitral regurgitation with a transcatheter procedure commonly used by interventional cardiologists. Launched on the market in mid-2022 with the objective of developing a limited sales network on the European market.
The company has developed a solid IP (global technology rights) and successful preclinical feasibility tests, support from the DGO6 | Amount sought: €691k
 
Sport tech - The 1st automatic distributor of sports care! 
A vending machine for sports products and its practitioners, installed directly on sports practice sites to facilitate access to this type of care, hygiene, maintenance and even health products!
A real sports parapharmacy accessible 24 hours a day, 7 days a week, fully automated with up-to-the-minute sales software, the latest payment technologies (no cash), lcd screen with photos and product information videos.
Innovative concept already supported by sports federations, cities, sports centres and professionals in the sector for rapid development on many Belgian and international sites!
+30 sites already signed and 2 machines already installed | Amount sought: 250 k€

Medtech - Shaking up Clinical Research
Advanced ePRO (electronic Patient Reported Outcomes) platform that assists the Clinical Research industry to efficiently access Real World Data (RWD) and Lifestyle patterns from IoT devices during studies, thus achieving up to 30% in cost savings and accelerating the drug development process for up to 2 years. Further to the advanced ePRO capabilities, this platform is using AI algorithms during clinical studies to predict outcomes based on derived behavioral biomarkers that deliver models of digital twin phenotypes. This pioneering approach will allow Pharmaceutical companies to simulate optimized studies with synthetic data based on previous clinical trials and deliver personalized interventions of high effectiveness.
Target: Pharmaceutical industries and CROs. Current product used by a Top5 Pharmaceutical company and 2 AI-driven studies designed, expected to be launched in 2020/Q1 | 1M€ sought 

Rédigé par Marie Dollé le Friday, December 13th 2019
 
Stay informed by suscribing to our newsletter